Payment overview · 2025
General Payments
$121.43
8 reported records · 5 companies
Healthcare provider profile · identity verified
Olimpia Rauta, MD
Allopathic & Osteopathic Physicians|Family Medicine · BISMARCK, ND · NPI 1043224348
Verified facts
What the public records show
CMS Open Payments records show Olimpia Rauta, MD received $121.43 in general payments during 2025 across 8 reported records.
Exact Sciences Corporation accounted for 27.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.15 | 27.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.39 | 24.2% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.07 | 20.6% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.81 | 15.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.01 | 12.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $121.43 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $29.39 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $29.39 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $25.07 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
83 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 347 | 73 |
| Atorvastatin Calcium | Atorvastatin Calcium | 284 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 277 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 267 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 245 | 71 |
| Omeprazole | Omeprazole | 198 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 198 | 57 |
| Lisinopril | Lisinopril | 180 | 52 |
| Losartan Potassium | Losartan Potassium | 156 | 52 |
| Meloxicam | Meloxicam | 137 | 42 |
| Metformin Hcl Er | Metformin Hcl | 127 | 34 |
| Sertraline Hcl | Sertraline Hcl | 108 | 30 |
| Furosemide | Furosemide | 106 | 34 |
| Gabapentin | Gabapentin | 102 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 101 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 96 | 35 |
| Montelukast Sodium | Montelukast Sodium | 96 | 24 |
| Eliquis | Apixaban | 83 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 23 |
| Alendronate Sodium | Alendronate Sodium | 78 | 26 |
| Potassium Chloride | Potassium Chloride | 72 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 71 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 35 |
| Simvastatin | Simvastatin | 66 | 23 |
| Trazodone Hcl | Trazodone Hcl | 61 | 20 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 59 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 50 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 50 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | suppressed |
| Famotidine | Famotidine | 47 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 44 | suppressed |
| Allopurinol | Allopurinol | 43 | 14 |
| Metformin Hcl | Metformin Hcl | 43 | 20 |
| Jardiance | Empagliflozin | 42 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 13 |
| Finasteride | Finasteride | 38 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 17 |
| Glipizide Er | Glipizide | 37 | 11 |
| Klor-Con M20 | Potassium Chloride | 35 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | 12 |
| Mirtazapine | Mirtazapine | 29 | 15 |
| Carvedilol | Carvedilol | 28 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 22 | 15 |
| Lorazepam | Lorazepam | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 19 | 19 |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Prednisone | Prednisone | 19 | 14 |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 14 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $121.43 · 8 records | Exact Sciences Corporation | Cologuard Collection Kit, EVENITY, GVOKE HYPOPEN, NURTEC ODT, The Cologuard Plus Collection Kit, VOQUEZNA, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error